Andrew McClary
Founder and Managing Partner @ KdT Ventures
Asheville, United States
Andrew McClary is a seed investor at KdT Ventures in Asheville focused on Biotechnology and Life Science. Andrew Cain McClary is based out of Austin, Texas, and is the Founder and Managing Partner of KdT Ventures. Andrew previously worked at Tulane University School of Medicine as a Clinical Instructor and Visiting Professor. Andrew Cain McClary attended the Stanford University School of Medicine.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Andrew McClary invests in
Stages Andrew McClary invests in
Countries Andrew McClary invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 5 (71%)
- Life Science 4 (57%)
- Biopharma 2 (29%)
- Health Care 2 (29%)
- Advanced Materials 1 (14%)
Stage
- Seed 4 (57%)
- Series B 2 (29%)
- Series A 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Biopharmaceutical research and development company that's an affiliate of Clover Health | $93M / Series B / Mar 25, 2025 | ||
| Elegen is a biotechnology company that develops microfluidic technology. It is driven by a mission to deploy this technology in a new generation of DNA synthesizers aimed at enabling and accelerating biomedical advances. The company was founded in 2017 and led by Dr. Matthew Hill. | $35M / Series B / May 14, 2024 | ||
| Biopharmaceutical research and development company that's an affiliate of Clover Health | $6M / Seed / Apr 01, 2020 | ||
| Checkerspot is a materials innovation company. Advances in our understanding of biology, chemistry and materials science are converging with breakthroughs in data science and unleashing capabilities they once only imagined. Checkerspot's technology unlocks this potential, expands the palette of materials available to product designers andenables a more intentional way to design performance materials for specific applications. As a graduate of the Illumina Accelerator program, we are building a technology platform that enables the design – at a molecular level – of new materials. Through applications development, they prototype and iterate on specific product embodiments. By engaging directly with product users and partnering with socially responsible corporations, they design and bring to market superior products with better materials. | $13M / Series A / Apr 16, 2019 | ||
| Tierra Biosciences is a synthetic biology company that accelerates the pace of discovery and enables the next generation of bio-based materials. Tierra’s first product, the Tierra Protein Platform, couples high-throughput protein manufacturing with the simplicity of e-commerce to make ordering custom proteins easier than ever before. By loweringthe traditional protein synthesis barrier, Tierra serves scientists looking to change the world with novel proteins. Led by a team of protein experts, this fast-growing company is transforming the way people discover, screen, and develop proteins for future bio-based products. For more information, visit tierrabiosciences.com. | $2.6M / Seed / Sep 11, 2018 | ||
| Tierra Biosciences is an operator of a synthetic biology company intended to accelerate the pace of discovery to enable the next generation of bioengineered products. The company's protein platform leverages cell-free protein production and artificial intelligence and couples high-throughput protein manufacturing with the simplicity ofe-commerce. | $2.6M / Seed / Sep 11, 2018 | ||
| Checkerspot is a materials innovation company. Advances in our understanding of biology, chemistry and materials science are converging with breakthroughs in data science and unleashing capabilities they once only imagined. Checkerspot's technology unlocks this potential, expands the palette of materials available to product designers andenables a more intentional way to design performance materials for specific applications. As a graduate of the Illumina Accelerator program, we are building a technology platform that enables the design – at a molecular level – of new materials. Through applications development, they prototype and iterate on specific product embodiments. By engaging directly with product users and partnering with socially responsible corporations, they design and bring to market superior products with better materials. | $5M / Seed / Jun 21, 2018 |
Co-Investors
About KdT Ventures
KdT Ventures is an early-stage venture capital firm that invests in startups in the data, engineering, and biology sector, as well as healthcare technology systems, pharmaceuticals, biotechnology, agriculture, chemicals, gases, and life sciences. The firm was founded in 2017 in Austin, Texas by Cain McClary.
KdT Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Andrew McClary
Founder and Managing Partner
|
|||
Phil Grayeski
Principal
|
|||
|
Ally Gudeman
Head of Operations
|
|||
Isaac Stoner
Advisor & LP
|
|||
Mack Healy
Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Andrew McClary invest in?
Andrew McClary invests primarily in Biotechnology, Life Science and Biopharma startups, most often at Seed and Series B stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Andrew McClary?
Public channels for Andrew McClary include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Andrew McClary last invest?
The most recent investment recorded for Andrew McClary closed in Mar 2025. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
